Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma.

Bortezomib (V)-based regimens are standard first-line treatment options for multiple myeloma (MM), an incurable plasma cell malignancy. A common adverse reaction in patients receiving V is treatment-emergent peripheral neuropathy (TEPN), which can ne…

Preview only. Read the full abstract at the source